NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

1. NLS and partners advance iTOL-102 with FDA support for clinical trials. 2. BIRD Foundation approves additional funding for iTOL-102 development. 3. iTOL-102 aims to cure Type 1 diabetes without long-term immunosuppression. 4. NLS prepares for key clinical studies on diabetes therapies. 5. Dr. Eric Konofal receives recognition for contributions to pediatric sleep medicine.

Corporate Developments

80

13m saved

Insight

Article

FAQ

Why Bullish?

The approval of funding and FDA support enhances NLSP’s growth potential and market confidence. Historical trends indicate similar developments have positively influenced biopharma stocks in clinical stages, reflecting investor optimism.

How important is it?

The news directly relates to NLSP's potential market impact, especially with iTOL-102, raising investor interest. Ongoing developments in clinical trials usually attract attention and can lead to price increases.

Why Short Term?

Immediate funding and regulatory milestones suggest potential positive price action as clinical trials approach. This is indicated in similar past events where timely news leads to price increases.

Related Companies

KDST ITOL

Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 Diabetes that Would Circumvent the Need for Life-long Immunosuppression Drugs

ZURICH, July 17, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S. Binational Industrial Research and Development Foundation (the "Bird Foundation") has approved another milestone-based funding payment to Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing "off-the-shelf," allogeneic regenerative treatments for neurodegenerative diseases and diabetes, with a U.S.-based company, iTolerance, Inc. ("iTolerance"). The milestone payment is based on the significant progress demonstrated by the companies in the co-development of iTOL-102, a novel cell therapy targeting a potential cure for Type 1 diabetes without the need for life-long immunosuppression.